US Supreme Court Asked To Review Timing Of Biosimilar Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
In Zarxio case, Sandoz petitions high court to determine whether notice of biosimilar commercial marketing can be given before FDA approval; court may await rulings in pending cases interpreting the biosimilars statute.